Identification of Novel Stemness-based Subtypes and Construction of a Prognostic Risk Model for Patients with Lung Squamous Cell Carcinoma
- 1 April 2024
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Stem Cell Research & Therapy
- Vol. 19 (3) , 400-416
Abstract
Background: Although cancer stem cells (CSCs) contribute to tumorigenesis, progression, and drug resistance, stemness-based classification and prognostic signatures of lung squamous cell carcinoma (LUSC) remain unclarified. This study attempted to identify stemness-based subtypes and develop a prognostic risk model for LUSC. Methods: Based on RNA-seq data from The Cancer Genome Atlas (TCGA), Gene-Expression Omnibus (GEO) and Progenitor Cell Biology Consortium (PCBC), mRNA expression-based stemness index (mRNAsi) was calculated by one-class logistic regression (OCLR) algorithm. A weighted gene coexpression network (WGCNA) was employed to identify stemness subtypes. Differences in mutation, clinical characteristics, immune cell infiltration, and antitumor therapy responses were determined. We constructed a prognostic risk model, followed by validations in GEO cohort, pan-cancer and immunotherapy datasets. Results: LUSC patients with subtype C2 had a better prognosis, manifested by higher mRNAsi, higher tumor protein 53 (TP53) and Titin (TTN) mutation frequencies, lower immune scores and decreased immune checkpoints. Patients with subtype C2 were more sensitive to Imatinib, Pyrimethamine, and Paclitaxel therapy, whereas those with subtype C1 were more sensitive to Sunitinib, Saracatinib, and Dasatinib. Moreover, we constructed stemness-based signatures using seven genes (BMI1, CCDC51, CTNS, EIF1AX, FAM43A, THBD, and TRIM68) and found high-risk patients had a poorer prognosis in the TCGA cohort. Similar results were found in the GEO cohort. We verified the good performance of risk scores in prognosis prediction and therapy responses. Conclusion: The stemness-based subtypes shed novel insights into the potential roles of LUSC-stemness in tumor heterogeneity, and our prognostic signatures offer a promising tool for prognosis prediction and guide therapeutic decisions in LUSC.Keywords
This publication has 53 references indexed in Scilit:
- pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression LevelsPLOS ONE, 2014
- Non-small-cell lung cancers: a heterogeneous set of diseasesNature Reviews Cancer, 2014
- Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non–Small-Cell Lung Cancer Including Stage IA PatientsJournal of Thoracic Oncology, 2014
- Inferring tumour purity and stromal and immune cell admixture from expression dataNature Communications, 2013
- Ectopic Activation of Germline and Placental Genes Identifies Aggressive Metastasis-Prone Lung CancersScience Translational Medicine, 2013
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray ValidationClinical Cancer Research, 2013
- The sva package for removing batch effects and other unwanted variation in high-throughput experimentsBioinformatics, 2012
- Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Non–Small-Cell Lung Cancer PatientsClinical Cancer Research, 2011
- WGCNA: an R package for weighted correlation network analysisBMC Bioinformatics, 2008